7/19/2006

The FDA requires more information from MedImmune about the liquid version of its inhaled FluMist flu vaccine, the company says, adding it does not expect a delay in approval. A spokeswoman said the agency has requested technical clarification of submitted clinical and testing data.

Related Summaries